반응식
[O:1]=[C:2]1[NH:7][C:6]2[CH:8]=[C:9]([C:11]3[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=3)[S:10][C:5]=2[C:4](=[O:17])[N:3]1[CH:18]1[CH2:23][CH2:22][N:21]([C:24]([O:26][C:27]([CH3:30])([CH3:29])[CH3:28])=[O:25])[CH2:20][CH2:19]1.Cl[CH2:32][C:33]1[N:37]=[C:36]([CH3:38])[O:35][N:34]=1.C(=O)([O-])[O-].[K+].[K+]>CN(C=O)C>[CH3:38][C:36]1[O:35][N:34]=[C:33]([CH2:32][N:7]2[C:6]3[CH:8]=[C:9]([C:11]4[CH:16]=[CH:15][CH:14]=[CH:13][CH:12]=4)[S:10][C:5]=3[C:4](=[O:17])[N:3]([CH:18]3[CH2:23][CH2:22][N:21]([C:24]([O:26][C:27]([CH3:30])([CH3:29])[CH3:28])=[O:25])[CH2:20][CH2:19]3)[C:2]2=[O:1])[N:37]=1참가 물질
5
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
According to GP1 tert-butyl 4-(2,4-dioxo-6-phenyl-1,4-dihydrothieno[3,2-d]pyrimidin-3(2H)-yl)piperidine-1-carboxylate (200 mg; compound B50) is reacted with 3-(chloromethyl)-5-methyl-1,2,4-oxadiazole (62 mg; compound D2) in the presence of potassium carbonate (65 mg) in DMF (5 ml). Using WU1 the title compound is obtained as a solid.
출처 및 근거
- ORD 기록
- ord-07674ff8ed0d4e96b13d82054d83a46c
- 출처 데이터셋
- uspto-grants-2015_04
- 특허 번호
- US09018175B2
연결된 노트
불러오는 중…